While its precise role in GBM remains to be established, in relation to G-1-initiated signaling, increased ANGPTL4 expression appears to be a robust marker of exposure to this GPER agonist, especially in U251 cells. This evidence concerns the gene ANGPTL4 and glioblastoma.